InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,231.60
(
-0.14%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
-0.72%
)
Bitcoin
64,152.64
(
-1.03%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 3425

Sunday, 08/05/2007 11:50:37 PM

Sunday, August 05, 2007 11:50:37 PM

Post# of 19309
NovoSeven update from 2Q07 CC:

“It’s not a secret that our NovoSeven
business has a very attractive gross margin.”
—Lars Rebien Sørensen, CEO of Novo Nordisk, on last week’s CC

NovoSeven sales in 1H07 rose 11% in local currencies vs 1H06 (+5% in DKK) to $535B. In 2Q07, sales were $277M (a $1.1B annualized rate), +7% vs 1Q07.

In the U.S., approximately 20% of NovoSeven sales are off-label.

Sales growth in 2008 is expected to slow somewhat due to increased use of high-dose FVIII/FIX concentrates (rather than FVIIa) to overcome inhibitors to FVIII/FIX by the “brute force” method.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up